Semaglutide, a GLP-1 receptor analogue (GLP-1 RA), indicated for the management of type 2 diabetes has been developed in an oral formulation for the first time. Oral semaglutide will be a gamechanger for people with type 2 diabetes who prefer oral medications over injections. was
POST TAGS:
Bhatia Hospital & Joshi CliniccardiologyChair IDF Southeast Asia and Consultant Endocrinologist at Lilavati HospitalChairmanChennaiCorporate Vice President and Managing DirectorDelhi saiddiagnosedDr. Mohan's Diabetes Specialities CentreDr. Shashank JoshiDr. V. MohanDr. Vinay Kumar Bahlhealthcare companyinjectablesMax hospitalMumbaiNovo Nordisk IndiaNovo Nordisk India launches world’s first and only GLP-1 RAoralOral Semaglutide- a gamechanger in diabetesPrincipal Directortarget blood sugarVikrant Shrotriya